OncoLab Co., Ltd. announced that it secured Pre-A funding (USD 1M) at the end of September. This funding marks a key milestone in advancing the company’s ANGel precision immuno-oncology platform toward GLP toxicology, manufacturing scale-up, and IND preparation.
Dr. Jongseong Kim, Founder and CEO of OncoLab, said:
“This investment milestone reflects strong confidence in the ANGel platform’s global potential. We will continue to strengthen our clinical readiness and expand international partnerships to accelerate our mission of advancing precision immunotherapy.”